BIOMAT Database Logo BIOMAT Database Logo

Prevention of type I diabetes in the non-obese diabetic (NOD) mouse with 15-deoxyspergualin (15-DS) or 15-DS + cyclosporin A (CyA). 1995

J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Chirurgische Universitätsklinik, Freiburg, Germany.

By selectively inbreeding diabetic individuals, we have been able to establish an NOD mouse population with a genetic predisposition towards insulin-dependent diabetes mellitus (IDDM) in approximately 100% of cases. We examined the preventive effect of 15-DS or 15DS + CyA on developing IDDM in these animals. Whereas 15-DS has been proved to be effective in preventing diabetes (significant decrease of the diabetic risk ratio to 0.368 and a reduction of the incidence of the disease to 46.7%), combined treatment with CyA did not produce any additional benefit.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse.
October 1991, Scandinavian journal of immunology,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes.
January 2002, Diabetes/metabolism research and reviews,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
The non-obese diabetic (NOD) mouse as a model of human type 1 diabetes.
January 2012, Methods in molecular biology (Clifton, N.J.),
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
[NOD mouse (non-obese diabetic mouse)].
January 1998, Nihon rinsho. Japanese journal of clinical medicine,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Non-obese diabetic (NOD) mouse.
August 1996, The American journal of pathology,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin.
February 1993, Clinical and experimental immunology,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
The non-obese diabetic (NOD) mouse.
August 1987, The American journal of pathology,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Paquinimod prevents development of diabetes in the non-obese diabetic (NOD) mouse.
January 2018, PloS one,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes.
January 2016, Journal of autoimmunity,
J Haberstroh, and T Wilhelm, and J Schulte-Mönting, and H U Schorlemmer, and B U von Specht
Immunotherapy with ciamexon in the non obese diabetic (NOD) mouse.
January 1992, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!